The CVD-REAL Nordic study also observed a reduced risk of hospitalisations for HF with SGLT2 inhibitors compared to other diabetes drugs (HR 0.70; 95% CI 0.61, 0.81; p < 0.0001) [47]. Here, SLC5A2 is linked to diabetes mellitus.